Shares of Reunion Neuroscience Inc. (NASDAQ:REUN – Get Rating) shot up 4.5% during trading on Friday . The stock traded as high as $1.44 and last traded at $1.41. 54,642 shares changed hands during mid-day trading, a decline of 55% from the average session volume of 121,460 shares. The stock had previously closed at $1.35.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on the company. Bloom Burton reiterated a "buy" rating on shares of Reunion Neuroscience in a research report on Monday, November 28th. Stifel Nicolaus cut their price objective on Reunion Neuroscience from C$15.00 to C$5.50 in a research report on Tuesday, November 15th. Finally, EF Hutton Acquisition Co. I assumed coverage on Reunion Neuroscience in a research report on Friday, December 16th. They issued a "buy" rating and a $11.00 price objective for the company.
Get
Reunion Neuroscience alerts:
Reunion Neuroscience Stock Up 4.5 %
The stock's 50-day simple moving average is $1.25.
Reunion Neuroscience (NASDAQ:REUN – Get Rating) last released its earnings results on Monday, November 14th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.50). As a group, equities analysts expect that Reunion Neuroscience Inc. will post -1.62 earnings per share for the current year.
Institutional Investors Weigh In On Reunion Neuroscience
A number of institutional investors and hedge funds have recently made changes to their positions in the company. Cidel Asset Management Inc. bought a new stake in shares of Reunion Neuroscience during the third quarter worth $29,000. Jane Street Group LLC acquired a new stake in shares of Reunion Neuroscience during the third quarter worth $51,000. Finally, One Plus One Wealth Management LLC acquired a new stake in shares of Reunion Neuroscience during the third quarter worth $109,000. Institutional investors own 12.88% of the company's stock.
About Reunion Neuroscience
(Get Rating)
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions.
Read More
- Get a free copy of the StockNews.com research report on Reunion Neuroscience (REUN)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
- Carvana Stock Rally, Here's What You Need to Know
Receive News & Ratings for Reunion Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reunion Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
